BR100 Increased By (0.36%)
BR30 Increased By (0.28%)
KSE100 Increased By (0.24%)
KSE30 Increased By (0.13%)
BECO 6.03 No Change ▼ 0.00 (0%)
BML 57.29 Increased By ▲ 4.54 (8.61%)
BOP 34.15 Decreased By ▼ -0.10 (-0.29%)
CNERGY 8.21 Increased By ▲ 0.05 (0.61%)
DCL 12.22 Decreased By ▼ -0.12 (-0.97%)
FCCL 53.90 Increased By ▲ 0.01 (0.02%)
FCSC 5.28 Increased By ▲ 0.06 (1.15%)
FFL 18.00 Decreased By ▼ -0.03 (-0.17%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.23 Increased By ▲ 0.23 (2.09%)
KEL 8.14 Increased By ▲ 0.03 (0.37%)
KOSM 5.46 Increased By ▲ 0.08 (1.49%)
MLCF 88.65 Increased By ▲ 0.60 (0.68%)
NBP 186.15 Decreased By ▼ -0.33 (-0.18%)
PACE 10.86 Increased By ▲ 0.14 (1.31%)
PAEL 40.59 Increased By ▲ 0.65 (1.63%)
PIAHCLA 26.26 Increased By ▲ 0.09 (0.34%)
PIBTL 17.36 Increased By ▲ 0.04 (0.23%)
PPL 232.74 Decreased By ▼ -0.04 (-0.02%)
PRL 34.82 Decreased By ▼ -0.13 (-0.37%)
PTC 66.78 Decreased By ▼ -0.78 (-1.15%)
SEARL 91.56 Increased By ▲ 0.63 (0.69%)
SSGC 27.16 Decreased By ▼ -0.01 (-0.04%)
TELE 8.57 No Change ▼ 0.00 (0%)
THCCL 64.48 Increased By ▲ 4.35 (7.23%)
TPLP 9.14 Increased By ▲ 0.38 (4.34%)
TREET 24.68 Increased By ▲ 0.14 (0.57%)
TRG 72.70 Increased By ▲ 0.95 (1.32%)
WAVES 10.70 Increased By ▲ 0.72 (7.21%)
WTL 1.27 Increased By ▲ 0.01 (0.79%)
By

TASHKENT: Uzbekistan has arrested four people in an investigation into the deaths of 19 children who consumed cough syrup made by Indian drug maker Marion Biotech, the Uzbek state security service said on Friday.

Two of the detained were senior employees of the Scientific Center for Standardization of Medicines, who circumvented the proper testing procedures for the Doc-1 Max cough syrup, it said.

Two others were executives of the Quramax Medikal company that imported the Marion Biotech drugs.

Marion Biotech said last month, shortly after the series of deaths, that it had halted production of the syrup.

India probes cough syrup blamed for Uzbek child deaths

Uzbekistan’s health ministry had said the syrup contained a toxic substance, ethylene glycol, and was administered in doses higher than the standard dose for children, either by their parents, who mistook it for an anti-cold remedy, or on the advice of pharmacists.

The Uzbekistan case follows deaths of at least 70 children in Gambia that a parliamentary committee had linked to cough and cold syrups manufactured by New Delhi-based Maiden Pharmaceuticals. The company denied any wrongdoing and Indian government inspectors found no contamination in test samples.

Comments

Comments are closed for this article.